Text Size

Eyelid Closure in Glaucoma Therapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Henry D. Jampel, M.D., M.H.S., Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00832832
First received: January 29, 2009
Last updated: September 19, 2012
Last verified: September 2012
History of Changes
  Purpose

This research is being done to determine if closing your eyelids after you take your glaucoma drops makes them more effective in lowering your eye pressure, and to determine if closing your eyelids for 5 minutes is better than closing them for one minute


Condition Intervention
Glaucoma
 Other: Eyelid closure
Other: No intervention will be assigned

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Eyelid Closure in Topical Glaucoma Therapy

Resource links provided by NLM:

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Amount of intraocular pressure lowering [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Amount of intraocular pressure lowering [ Time Frame: 1 hour and one week ] [ Designated as safety issue: No ]

Enrollment: 60
Study Start Date: January 2009
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eyelid closure
Eyelids will be closed after administration of eye drop
 Other: Eyelid closure
Eyelid will be closed after eye drop instillation
Active Comparator: No eyelid closure
Eyelids will not be closed after eye drop instillation
 Other: No intervention will be assigned
No intervention will be assigned to this arm
Other Name: No intervention needed in Arm 2

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age over 18 years, use of one of the three topical prostaglandins (latanoprost, travaprost, or bimatoprost), and no other IOP-lowering eye drops for at least one month.

Exclusion Criteria:

  • Previous laser or incisional surgery for glaucoma, use of punctual plugs, an abnormal slit lamp exam (except for cataract or intraocular lens implant) and incisional eye surgery within the last 6 months.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00832832

Locations
United States, Maryland
Johns Hopkins - The Wilmer Eye Institute
Baltimore, Maryland, United States, 21009
Sponsors and Collaborators
Johns Hopkins University
Investigators
Principal Investigator: Henry D Jampel, MD Johns Hopkins University
  More Information

No publications provided

Responsible Party: Henry D. Jampel, M.D., M.H.S., Professor, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00832832     History of Changes
Other Study ID Numbers: NA_00021272
Study First Received: January 29, 2009
Last Updated: September 19, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Johns Hopkins University:
Glaucoma
Eye drop
Intraocular pressure
Eyelid closure

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases

ClinicalTrials.gov processed this record on May 22, 2013